Search

Displaying results 9291 - 9300 of 9686 in total
  1. Drug

    Phloretin

    go.drugbank.com/drugs/DB07810
    Experimental

    Phloretin is a natural dihydrochalcone found in apples and many other fruits.

  2. Drug

    (R)-warfarin

    go.drugbank.com/drugs/DB08496
    Experimental

    Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.

  3. Drug

    Antazoline

    go.drugbank.com/drugs/DB08799
    Approved

    Antazoline is a 1st generation antihistamine with anticholinergic activity. It is used to relieve nasal congestion.

    Mixtures: Albalon A, Zincfrin AInternational brands: Vasocon-a
  4. Drug

    Isothipendyl

    go.drugbank.com/drugs/DB08802
    Investigational

    Isothipendyl is an antihistamine and anticholinergic used as an antipruritic.

  5. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  6. Drug

    Gabapentin enacarbil

    go.drugbank.com/drugs/DB08872
    Approved

    It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).

  7. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    Perampanel is a noncompetitive AMPA glutamate receptor antagonist.

  8. Drug

    Ocriplasmin

    go.drugbank.com/drugs/DB08888
    ApprovedWithdrawn

    Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.

  9. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...

    Categories: UGT1A9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  10. Drug

    Bedaquiline

    go.drugbank.com/drugs/DB08903
    ApprovedInvestigational

    Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline.